Trials / Completed
CompletedNCT01990248
An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)
ZeSS: A Prospective Observational Safety Study of Patients With BRAF-V600 Mutation-positive Unresectable or Metastatic Melanoma Treated With Vemurafenib (Zelboraf®)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 339 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This multi-center, prospective, observational safety study will evaluate the safety and effectiveness of Zelboraf (vemurafenib) in a real world setting. Data from Zelboraf-treated patients with BRAF-V600 mutation-positive unresectable or metastatic melanoma will be collected for 2 years.
Conditions
Timeline
- Start date
- 2013-03-23
- Primary completion
- 2016-07-26
- Completion
- 2016-07-26
- First posted
- 2013-11-21
- Last updated
- 2018-06-19
Locations
80 sites across 10 countries: Austria, Belgium, Czechia, Germany, Ireland, Italy, Netherlands, Poland, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT01990248. Inclusion in this directory is not an endorsement.